Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase II study of Bevacizumab with SOX (S-1 plus L-OHP) as second-line therapy in metastatic colorectal cancer

ABSTRACT: Interventions: Bevacizumab with SOX (S-1 plus L-OHP) repeat every 21 days until discontinuance criteria. Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2620638 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

L-OHP resistant gastric cancer organoid

Project description:The attainment of drug resistance in gastric cancer (GC) is a problematic issue. Although many studies have shown that cancer stem cells (CSCs) play an important role in the acquisition of drug resistance, there is no clinically available biomarker for predicting oxaliplatin (L-OHP) resistance in relation to CSCs. Organoid technology, a novel 3D cell culture system, allows harboring of patient-derived cancer cells containing abundant CSCs using niche factors in a dish. In this study, we established L-OHP-resistant gastric cancer organoids (GCOs) and evaluated their gene expression profile using microarray analysis. We validated the upregulated genes in the L-OHP-resistant GCOs compared to their parental GCOs to find a gene responsible for L-OHP resistance by qRT-PCR, immunohistochemistry, in vitro, and in vivo experiments. We found myoferlin (MYOF) to be a candidate gene through microarray analysis. The results from cell viability assays and qRT-PCR showed that high expression of MYOF correlated significantly with the IC50 of L-OHP in GCOs. Immunohistochemistry of MYOF in GC tissue samples revealed that high expression of MYOF was significantly associated with poor prognosis, T grade, N grade, and lymphatic invasion, and showed MYOF to be an independent prognostic indicator, especially in the GC patients treated with platinum-based chemotherapy. The knockdown of MYOF repressed L-OHP resistance, cell growth, stem cell features, migration, invasion, and in vivo tumor growth. Our results suggest that MYOF is highly involved in L-OHP resistance and tumor progression in GC. MYOF could be a promising biomarker and therapeutic target for L-OHP-resistant GC cases.

2024-12-25 | GSE280740 | GEO

L-OHP resistant gastric cancer organoid

Project description:L-OHP resistant gastric cancer organoid

| PRJNA1180444 | ENA

Panarthropod Sox genes

Project description:Embryonic expression patterns of panarthropod Sox genes

| PRJEB22589 | ENA

Sequentially acting Sox transcription factors in neural lineage development

Project description:This SuperSeries is composed of the following subset Series: GSE33059: Sequentially acting Sox transcription factors in neural lineage development [ChIP-seq] GSE33060: Sequentially acting Sox transcription factors in neural lineage development [RNA-seq] GSE33061: Sequentially acting Sox transcription factors in neural lineage development [microarray] Refer to individual Series

2011-11-01 | E-GEOD-33024 | biostudies-arrayexpress

Ribo-seq of human colorectal cancer cell line HCT116/L-OHP against HCT116

Project description:Oxaliplatin (L-OHP) serves as a standard chemotherapy for colorectal cancer, while the drug resistance is still a considerable challenge. Dysregulation of lncRNA is involved in cancer and recent translatomics has found some alleged lncRNA actually contained small open reading frames and could encode short peptides. This ribosome footprint profiling (Ribo-seq) was a paired-end sequencing and aimed to investigate whether lncRNA could regulate oxaliplatin resistance in colorectal cancer by encoding short peptides.

2021-11-12 | E-MTAB-10805 | biostudies-arrayexpress

SOX

Project description:Arabidopsis thaliana SOX, Sulfite oxidase [Source:UniProtKB/TrEMBL;Acc:Q0WWA1], is expressed in 15 baseline experiment(s);

| AT3G01910 | ExpressionAtlas

SOX

Project description:Arabidopsis thaliana SOX, Sulfite oxidase [Source:UniProtKB/TrEMBL;Acc:Q0WWA1], is differentially expressed in 44 experiment(s);

| AT3G01910 | ExpressionAtlas

RNA-seq of human colorectal cancer cell line HCT116/L-OHP against HCT116

Project description:Oxaliplatin (L-OHP) serves as a standard chemotherapy for colorectal cancer, while the drug resistance is still a considerable challenge. A number of previously unknown transcripts have been identified in recent years, the vast majority of which are considered long non-coding RNA (lncRNA). Dysregulation of the lncRNA is involved in the genesis and progression of cancer. This RNA-seq was a paired-end sequencing and aimed to investigate the expression profile of lncRNA associated with oxaliplatin resistance in colorectal cancer.

2021-11-12 | E-MTAB-10806 | biostudies-arrayexpress

sox-2

Project description:Caenorhabditis elegans sox-2, Transcription factor sox-2 [Source:UniProtKB/Swiss-Prot;Acc:Q21305], is differentially expressed in 2 experiment(s);

| WBGene00004949 | ExpressionAtlas

sox-2

Project description:Caenorhabditis elegans sox-2, Transcription factor sox-2 [Source:UniProtKB/Swiss-Prot;Acc:Q21305], is expressed in 1 baseline experiment(s);

| WBGene00004949 | ExpressionAtlas

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data